Arnout Ploos van Amstel
Gründer bei Moonlake Immunotherapeutics AG
Vermögen: 72 400 $ am 30.04.2024
Profil
Arnout Ploos van Amstel is the founder of Moonlake Immunotherapeutics AG, which is founded in 2021, where he holds the title of Chief Operating Officer.
He is currently the Chief Operating Officer at Khondrion BV since 2019.
Mr. Ploos van Amstel's former positions include being an Independent Director at JATT Acquisition Corp., Senior VP & General Manager-Hospital Business at Wyeth Pharmaceuticals LLC, and SVP & GM-Global Business Franchise Immunology at Novartis AG.
Mr. Ploos van Amstel received his undergraduate degree from the University of Groningen.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
ZURA BIO LIMITED CLASS A
0,05% | 25.03.2024 | 20 000 ( 0,05% ) | 72 400 $ | 30.04.2024 |
Aktive Positionen von Arnout Ploos van Amstel
Unternehmen | Position | Beginn |
---|---|---|
Khondrion BV
Khondrion BV Pharmaceuticals: MajorHealth Technology Khondrion BV is a Dutch clinical-stage biopharmaceutical company that focuses on discovering and developing therapies for mitochondrial diseases. The company is based in Nijmegen, Netherlands, and was founded in 2012 by Jan Smeitink, who has been the CEO since then. The company's lead drug candidate, sonlicromanol, is a first-in-class, oral small molecule that targets key underlying mechanisms of primary mitochondrial disease. The compound has been granted orphan drug designations for the treatment of various mitochondrial diseases. Khondrion collaborates with a clinical and academic network and patient organizations internationally to accelerate the discovery and development of its potential medicines. | Geschäftsführer | 10.12.2019 |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | Gründer | 01.01.2021 |
Ehemalige bekannte Positionen von Arnout Ploos van Amstel
Unternehmen | Position | Ende |
---|---|---|
NOVARTIS AG | Corporate Officer/Principal | - |
Wyeth Pharmaceuticals LLC
Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | Corporate Officer/Principal | - |
JATT ACQUISITION CORP | Direktor/Vorstandsmitglied | - |
Ausbildung von Arnout Ploos van Amstel
University of Groningen | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
NOVARTIS AG | Health Technology |
Private Unternehmen | 4 |
---|---|
Wyeth Pharmaceuticals LLC
Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | Health Technology |
Khondrion BV
Khondrion BV Pharmaceuticals: MajorHealth Technology Khondrion BV is a Dutch clinical-stage biopharmaceutical company that focuses on discovering and developing therapies for mitochondrial diseases. The company is based in Nijmegen, Netherlands, and was founded in 2012 by Jan Smeitink, who has been the CEO since then. The company's lead drug candidate, sonlicromanol, is a first-in-class, oral small molecule that targets key underlying mechanisms of primary mitochondrial disease. The compound has been granted orphan drug designations for the treatment of various mitochondrial diseases. Khondrion collaborates with a clinical and academic network and patient organizations internationally to accelerate the discovery and development of its potential medicines. | Health Technology |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | Health Technology |
JATT Acquisition Corp.
JATT Acquisition Corp. Financial ConglomeratesFinance JATT Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded by Someit Sidhu on March 10, 2021 and is headquartered in George Town, Cayman Islands. | Finance |